Boehringer Ingelheim reports positive data from real-world Pradaxa study

Boehringer Ingelheim has announced results of a new interim analysis from a long-term study showing the real-world benefits offered by Pradaxa.

Conducted in partnership with Brigham and Women's Hospital in Boston, the study evaluated the safety and effectiveness of the novel oral anticoagulant (NOAC) relative to warfarin in routine clinical practice, drawing data from more than 44,000 patients.

It showed that patients with non-valvular atrial fibrillation (AF) treated with Pradaxa had fewer strokes and fewer major bleeding events compared to AF patients treated with warfarin.

Pradaxa was associated with 28 percent and 26 percent reductions in stroke risk and major bleeding events compared to warfarin, respectively, underlining its proven benefits in routine care.

Professor Jorg Kreuzer, vice-president for cardiovascular medicine at Boehringer Ingelheim, said: "This data adds to the robust world of evidence supporting the real-world value of Pradaxa, the only NOAC with both proven superiority to warfarin in reducing stroke risk in AF patients and a specific reversal agent."

Idarucizumab, its new reversal agent for Pradaxa, has been recommended for European regulatory approval, and will be sold under the brand name Praxbind.